The ratio of leptin to adiponectin can be used as an index of insulin resistance

Naohisa Oda, Shigeo Imamura, Takashi Fujita, Yuka Uchida, Kazumichi Inagaki, Hiroaki Kakizawa, Nobuki Hayakawa, Atsushi Suzuki, Jun Takeda, Yukio Horikawa, Mitsuyasu Itoh

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

The level of leptin increases with obesity, whereas that of adiponectin decreases with obesity. It is reported that the ratio of leptin to adiponectin (L/A) is associated with insulin resistance. It is difficult to evaluate insulin resistance in diabetic patients who have a dysfunction of insulin secretion. The aim of this study was to examine whether the L/A ratio is a useful marker for insulin resistance in diabetic patients. We examined L/A in the serum of a total of 139 Japanese patients with type 2 diabetes mellitus (66 women and 73 men) and 7 healthy individuals recruited in our hospital. Changes in the levels of leptin and adiponectin were observed using the oral glucose tolerance test and a hyper- and euglycemic clamp test. Twenty-one patients with type 2 diabetes mellitus were observed for more than 6 months after treatment with pioglitazone, and 31 patients with type 2 diabetes mellitus were observed for more than 6 months after the treatment with metformin. The mean value of L/A in 139 Japanese patients with type 2 diabetes mellitus was 1.22 ± 1.41 (1.68 ± 1.76 in women, 0.81 ± 0.80 in men; P = .0002). In the clamp tests, L/A correlated with glucose infusion rate (GIR) (r2 = 0.26, P = .0034). The correlation of L/A and GIR indicated a stronger correlation than either leptin (r2 = 0.144, P = .03) or adiponectin alone (r2 = 0.023, P = .41), or the homeostasis model assessment of insulin resistance (r2 = 0.103, P = .08). The average hemoglobin A1c (HbA1c) improved from 10.2% ± 1.2% to 9.2% ± 1.6% (P = .0037) in 6 months after treatment with pioglitazone. Our results indicate pioglitazone to be effective for HbA1c improvement in subjects with high L/A and low L/A. The average HbA1c improved from 9.2% ± 0.9% to 8.0% ± 1.2% (P = .0002) in 6 months after treatment with metformin. Our results indicate metformin to be effective for HbA1c improvement in subjects with a low L/A. In conclusion, we demonstrate that L/A is different between male and female subjects. The correlation of L/A and GIR by the euglycemic hyperinsulinemic clamp test suggests that L/A is a useful indicator for the choice of drug to treat diabetes mellitus.

Original languageEnglish
Pages (from-to)268-273
Number of pages6
JournalMetabolism: Clinical and Experimental
Volume57
Issue number2
DOIs
Publication statusPublished - 01-02-2008

Fingerprint

Adiponectin
Leptin
Insulin Resistance
pioglitazone
Type 2 Diabetes Mellitus
Metformin
Hemoglobins
Glucose Clamp Technique
Glucose
Obesity
Therapeutics
Glucose Tolerance Test
Diabetes Mellitus
Homeostasis

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Oda, N., Imamura, S., Fujita, T., Uchida, Y., Inagaki, K., Kakizawa, H., ... Itoh, M. (2008). The ratio of leptin to adiponectin can be used as an index of insulin resistance. Metabolism: Clinical and Experimental, 57(2), 268-273. https://doi.org/10.1016/j.metabol.2007.09.011
Oda, Naohisa ; Imamura, Shigeo ; Fujita, Takashi ; Uchida, Yuka ; Inagaki, Kazumichi ; Kakizawa, Hiroaki ; Hayakawa, Nobuki ; Suzuki, Atsushi ; Takeda, Jun ; Horikawa, Yukio ; Itoh, Mitsuyasu. / The ratio of leptin to adiponectin can be used as an index of insulin resistance. In: Metabolism: Clinical and Experimental. 2008 ; Vol. 57, No. 2. pp. 268-273.
@article{4a3b9a0a17bc4bde97d33124e87c4a0a,
title = "The ratio of leptin to adiponectin can be used as an index of insulin resistance",
abstract = "The level of leptin increases with obesity, whereas that of adiponectin decreases with obesity. It is reported that the ratio of leptin to adiponectin (L/A) is associated with insulin resistance. It is difficult to evaluate insulin resistance in diabetic patients who have a dysfunction of insulin secretion. The aim of this study was to examine whether the L/A ratio is a useful marker for insulin resistance in diabetic patients. We examined L/A in the serum of a total of 139 Japanese patients with type 2 diabetes mellitus (66 women and 73 men) and 7 healthy individuals recruited in our hospital. Changes in the levels of leptin and adiponectin were observed using the oral glucose tolerance test and a hyper- and euglycemic clamp test. Twenty-one patients with type 2 diabetes mellitus were observed for more than 6 months after treatment with pioglitazone, and 31 patients with type 2 diabetes mellitus were observed for more than 6 months after the treatment with metformin. The mean value of L/A in 139 Japanese patients with type 2 diabetes mellitus was 1.22 ± 1.41 (1.68 ± 1.76 in women, 0.81 ± 0.80 in men; P = .0002). In the clamp tests, L/A correlated with glucose infusion rate (GIR) (r2 = 0.26, P = .0034). The correlation of L/A and GIR indicated a stronger correlation than either leptin (r2 = 0.144, P = .03) or adiponectin alone (r2 = 0.023, P = .41), or the homeostasis model assessment of insulin resistance (r2 = 0.103, P = .08). The average hemoglobin A1c (HbA1c) improved from 10.2{\%} ± 1.2{\%} to 9.2{\%} ± 1.6{\%} (P = .0037) in 6 months after treatment with pioglitazone. Our results indicate pioglitazone to be effective for HbA1c improvement in subjects with high L/A and low L/A. The average HbA1c improved from 9.2{\%} ± 0.9{\%} to 8.0{\%} ± 1.2{\%} (P = .0002) in 6 months after treatment with metformin. Our results indicate metformin to be effective for HbA1c improvement in subjects with a low L/A. In conclusion, we demonstrate that L/A is different between male and female subjects. The correlation of L/A and GIR by the euglycemic hyperinsulinemic clamp test suggests that L/A is a useful indicator for the choice of drug to treat diabetes mellitus.",
author = "Naohisa Oda and Shigeo Imamura and Takashi Fujita and Yuka Uchida and Kazumichi Inagaki and Hiroaki Kakizawa and Nobuki Hayakawa and Atsushi Suzuki and Jun Takeda and Yukio Horikawa and Mitsuyasu Itoh",
year = "2008",
month = "2",
day = "1",
doi = "10.1016/j.metabol.2007.09.011",
language = "English",
volume = "57",
pages = "268--273",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "2",

}

Oda, N, Imamura, S, Fujita, T, Uchida, Y, Inagaki, K, Kakizawa, H, Hayakawa, N, Suzuki, A, Takeda, J, Horikawa, Y & Itoh, M 2008, 'The ratio of leptin to adiponectin can be used as an index of insulin resistance', Metabolism: Clinical and Experimental, vol. 57, no. 2, pp. 268-273. https://doi.org/10.1016/j.metabol.2007.09.011

The ratio of leptin to adiponectin can be used as an index of insulin resistance. / Oda, Naohisa; Imamura, Shigeo; Fujita, Takashi; Uchida, Yuka; Inagaki, Kazumichi; Kakizawa, Hiroaki; Hayakawa, Nobuki; Suzuki, Atsushi; Takeda, Jun; Horikawa, Yukio; Itoh, Mitsuyasu.

In: Metabolism: Clinical and Experimental, Vol. 57, No. 2, 01.02.2008, p. 268-273.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The ratio of leptin to adiponectin can be used as an index of insulin resistance

AU - Oda, Naohisa

AU - Imamura, Shigeo

AU - Fujita, Takashi

AU - Uchida, Yuka

AU - Inagaki, Kazumichi

AU - Kakizawa, Hiroaki

AU - Hayakawa, Nobuki

AU - Suzuki, Atsushi

AU - Takeda, Jun

AU - Horikawa, Yukio

AU - Itoh, Mitsuyasu

PY - 2008/2/1

Y1 - 2008/2/1

N2 - The level of leptin increases with obesity, whereas that of adiponectin decreases with obesity. It is reported that the ratio of leptin to adiponectin (L/A) is associated with insulin resistance. It is difficult to evaluate insulin resistance in diabetic patients who have a dysfunction of insulin secretion. The aim of this study was to examine whether the L/A ratio is a useful marker for insulin resistance in diabetic patients. We examined L/A in the serum of a total of 139 Japanese patients with type 2 diabetes mellitus (66 women and 73 men) and 7 healthy individuals recruited in our hospital. Changes in the levels of leptin and adiponectin were observed using the oral glucose tolerance test and a hyper- and euglycemic clamp test. Twenty-one patients with type 2 diabetes mellitus were observed for more than 6 months after treatment with pioglitazone, and 31 patients with type 2 diabetes mellitus were observed for more than 6 months after the treatment with metformin. The mean value of L/A in 139 Japanese patients with type 2 diabetes mellitus was 1.22 ± 1.41 (1.68 ± 1.76 in women, 0.81 ± 0.80 in men; P = .0002). In the clamp tests, L/A correlated with glucose infusion rate (GIR) (r2 = 0.26, P = .0034). The correlation of L/A and GIR indicated a stronger correlation than either leptin (r2 = 0.144, P = .03) or adiponectin alone (r2 = 0.023, P = .41), or the homeostasis model assessment of insulin resistance (r2 = 0.103, P = .08). The average hemoglobin A1c (HbA1c) improved from 10.2% ± 1.2% to 9.2% ± 1.6% (P = .0037) in 6 months after treatment with pioglitazone. Our results indicate pioglitazone to be effective for HbA1c improvement in subjects with high L/A and low L/A. The average HbA1c improved from 9.2% ± 0.9% to 8.0% ± 1.2% (P = .0002) in 6 months after treatment with metformin. Our results indicate metformin to be effective for HbA1c improvement in subjects with a low L/A. In conclusion, we demonstrate that L/A is different between male and female subjects. The correlation of L/A and GIR by the euglycemic hyperinsulinemic clamp test suggests that L/A is a useful indicator for the choice of drug to treat diabetes mellitus.

AB - The level of leptin increases with obesity, whereas that of adiponectin decreases with obesity. It is reported that the ratio of leptin to adiponectin (L/A) is associated with insulin resistance. It is difficult to evaluate insulin resistance in diabetic patients who have a dysfunction of insulin secretion. The aim of this study was to examine whether the L/A ratio is a useful marker for insulin resistance in diabetic patients. We examined L/A in the serum of a total of 139 Japanese patients with type 2 diabetes mellitus (66 women and 73 men) and 7 healthy individuals recruited in our hospital. Changes in the levels of leptin and adiponectin were observed using the oral glucose tolerance test and a hyper- and euglycemic clamp test. Twenty-one patients with type 2 diabetes mellitus were observed for more than 6 months after treatment with pioglitazone, and 31 patients with type 2 diabetes mellitus were observed for more than 6 months after the treatment with metformin. The mean value of L/A in 139 Japanese patients with type 2 diabetes mellitus was 1.22 ± 1.41 (1.68 ± 1.76 in women, 0.81 ± 0.80 in men; P = .0002). In the clamp tests, L/A correlated with glucose infusion rate (GIR) (r2 = 0.26, P = .0034). The correlation of L/A and GIR indicated a stronger correlation than either leptin (r2 = 0.144, P = .03) or adiponectin alone (r2 = 0.023, P = .41), or the homeostasis model assessment of insulin resistance (r2 = 0.103, P = .08). The average hemoglobin A1c (HbA1c) improved from 10.2% ± 1.2% to 9.2% ± 1.6% (P = .0037) in 6 months after treatment with pioglitazone. Our results indicate pioglitazone to be effective for HbA1c improvement in subjects with high L/A and low L/A. The average HbA1c improved from 9.2% ± 0.9% to 8.0% ± 1.2% (P = .0002) in 6 months after treatment with metformin. Our results indicate metformin to be effective for HbA1c improvement in subjects with a low L/A. In conclusion, we demonstrate that L/A is different between male and female subjects. The correlation of L/A and GIR by the euglycemic hyperinsulinemic clamp test suggests that L/A is a useful indicator for the choice of drug to treat diabetes mellitus.

UR - http://www.scopus.com/inward/record.url?scp=38049075329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049075329&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2007.09.011

DO - 10.1016/j.metabol.2007.09.011

M3 - Article

C2 - 18191059

AN - SCOPUS:38049075329

VL - 57

SP - 268

EP - 273

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 2

ER -